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Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2) protein, mainly as a
result of gene ampliﬁcation. The receptor tyrosine kinase is believed to play a critical role in the pathogenesis and further
proliferationofthesetumors.Theapplicationoftrastuzumab,ahumanizedmonoclonalantibodyagainsttheextracellulardomain
of HER2 protein, to HER2-positive metastatic breast cancer has signiﬁcantly improved treatment outcomes. Following this
success, several phase III trials have evaluated the role of trastuzumab in the adjuvant setting, with the result that trastuzumab
use is now the standard of care for most HER2-positive early breast cancer patients. In this paper, we review these pivotal
phase III trials. We also discuss unresolved issues in adjuvant treatment with trastuzumab, including target patient population,
sequentialorconcurrentusewithchemotherapyorradiation,treatmentduration,cardiotoxicity,andthepossibilityofeliminating
chemotherapy. Following conﬁrmation of its ability to partially overcome trastuzumab resistance, we also discuss the role of
lapatinib in adjuvant use.
1.Introduction
Breast cancer is the leading cause of cancer death among
women worldwide, with approximately one million new
cases reported each year[1, 2]. Approximately 20% of breast
cancer tumors show overexpression of human epidermal
growth factor receptor 2 (HER2) protein, which has been
repeatedly identiﬁed as a poor prognostic factor [3, 4].
Trastuzumab, a humanized monoclonal antibody which tar-
gets the extracellular domain of the HER2 protein, has un-
dergone intense clinical investigation since the late 1990s.
Clinical development of trastuzumab was initially focused
on treatment for HER2-positive metastatic breast cancers
in the mid-1990s. In the ﬁrst pivotal phase III study, pa-
tients were treated with doxorubicin or epirubicin and
cyclophosphamide (AC or EC) or paclitaxel with (N =
235) or without (N = 234) trastuzumab [5]. Results for
the trastuzumab-containing arm were superior to those
with chemotherapy alone in virtually all eﬃcacy parameters
assessed, including overall survival (median, 25.1 versus 20.3
months, P = 0.046; HR, 0.80) [5], which, together with
the results of other studies, led to the broad clinical adop-
tion of trastuzumab in single or combined use with anthra-
cyclines, taxanes, vinorelbine, or capecitabine for HER2-
positive metastatic breast cancer [6–8]. Following this suc-
cess in the metastatic setting, ongoing evaluation of trastuz-
umab in adjuvant settings for operable HER2-positive breast
cancers was started, and with the six randomized phase III
trials of the integration of trastuzumab into standard adju-
vant treatments completed to date, all but one reporting that
the addition of trastuzumab provided a signiﬁcant improve-
ment in eﬃcacy [9–16].
In this paper, we discuss the current status of trastuz-
umab therapy in adjuvant treatment for breast cancer. We
also discuss unresolved issues in adjuvant use, including
target patient population, sequential or concurrent use with
chemotherapy, duration of treatment, cardiotoxicity, and the
possibility of eliminating chemotherapy. Given that lapa-
tinib, a dual inhibitor of epidermal growth factor receptor
(EGFR)/HER2 tyrosine kinase, has been clinically proven
to overcome at least some resistance to trastuzumab in the
metastatic setting [17], we also discuss the potential role of2 Chemotherapy Research and Practice
lapatinibinadjuvanttreatment,alongwiththecurrentstatus
of a large ongoing randomized study.
2.Pathophysiology oftheHERFamilyin
Breast Cancer
HER2 is a receptor tyrosine kinase (RTK) belonging to the
HER family which consists of HER 1 through 4. With the
exception of HER2, each member of the HER family has
cognate-identiﬁed ligands. Ligand binding to extracellular
domains induces conformational changes in the receptor,
which enable the receptor to form a homo- or heterodimer
a n dt ob e c o m ea c t i v ea sa nR T K .E a c hd i m e rc a ns u b -
sequently trigger various intracellular signaling pathways,
including those of PI3K/Akt, Ras/Raf/MEK/ERK, and STATs,
whichallplayimportantrolesincellularoncogenicprocesses
such as proliferation, survival, motility, and angiogenesis.
Because of the lack of a cognate ligand, HER2 must
dimerize with other HER family members under physio-
logical conditions. HER2 is considered to be the preferred
dimerization partner for the other HER family members.
In addition, under conditions of overexpression, HER2 can
be constitutively active and transform normal cells in the
absence of a ligand [18, 19]. While HER2 can theoretically
form four diﬀerent types of dimers, namely, with HER1,
HER2,HER3,orHER4,theHER2/HER3heterodimeriscon-
sidered to be the most mitogenic and transforming [20–23].
HER2 is overexpressed in 20%–25% of breast cancers.
In preclinical studies, HER2 overexpression has been shown
to be associated with increased metastatic potential [24]
and resistance to chemotherapeutic drugs such as paclitaxel,
docetaxel, doxorubicin, 5-ﬂuorouracil, and etoposide [25,
26]. Clinically, HER2-overexpression has been shown to be
associated with poor disease-free survival and overall sur-
vival, and poor responsiveness to CMF- (cyclophosphamide,
methotrexate, and 5-ﬂuorouracil) like therapy [3, 4, 27,
28]. Gene ampliﬁcation is considered the main mechanism
of HER2 protein overexpression. HER2 has been reported
to require HER3 to drive breast cancer cell proliferation,
emphasizing the importance of the HER2/HER3 heterodim-
er complex mentioned above [29].
3. Mechanisms of Action of Trastuzumab
The mechanisms of action for trastuzumab can be roughly
divided into two categories: inhibition of intracellular sig-
naling and induction of an immune system-mediated anti-
tumor response. Given HER2’s eﬀect in triggering multiple
signaling pathways, its inhibition should theoretically lead
to the inactivation of those pathways. Although it is not
fully understood how trastuzumab inhibits HER2 activity,
some studies have suggested that the drug might promote
internalization and degradation of HER2 [30, 31]. Recent
studies have suggested that the HER2/HER3/PI3K complex
and subsequent PI3K-Akt signaling pathway play central
roles in cell proliferation in HER2-overexpressing cells and
that the disruption of this complex might accordingly be
the key molecular mechanism of action of trastuzumab
[32, 33]. Supporting the involvement of PI3K-Akt pathway
in trastuzumab action, studies suggested that activating
mutation of the PIK3CA gene, which codes the p110α cat-
alytic domain of PI3K, or loss of phosphatase and tensin
homolog deleted from chromosome 10 (PTEN), could cause
resistance to trastuzumab [34–36].
Data from several in vivo experiments have indicated
that trastuzumab is capable of mediating the induction of
immuneresponsessuchasantibody-dependentcellularcyto-
toxicity (ADCC) and complement-dependent cytotoxicity
[37]. With ADCC, immunoeﬀector cells expressing the Fcγ
receptor recognize and bind to the Fc domain of the IgG1
antibody (trastuzumab) and subsequently lyse cells (in this
case, tumor cells) attached to the antibody. Directly proving
the role of ADCC in trastuzumab’s activity is naturally
diﬃcult in patients. However, perhaps the most convincing
evidence of the contribution of ADCC to trastuzumab-
induced antitumor activity was provided by mice lacking
the FC receptor (FcR−/−), in which trastuzumab treatment
resulted in signiﬁcantly lower rates of tumor regression than
in FC receptor-expressing mice [38].
4. Role of Trastuzumab in Adjuvant Treatment
for Early Breast Cancer
4.1. Overview of Pivotal Phase III Randomized Trials. Fol-
lowing its successful application in HER2-positive metastatic
breast cancer, trastuzumab was subsequently tested in adju-
vant use. As of today, the results of six well-designed phase
III trials comparing nontrastuzumab adjuvant therapies
withtrastuzumab-containingtherapiesareavailableineither
conferenceabstractformorfullpaper(Table 1 andFigure 1).
The National Surgical Adjuvant Breast and Bowel Project
trial B-31 (NSABP B-31) compared four cycles of doxoru-
bicin and cyclophosphamide (AC) followed by four cycles of
triweekly paclitaxel (tri-PTX) (Arm 1, reference arm) with
the same regimen plus 52 weeks of weekly trastuzumab
(wkly-HER)beginningonday1oftri-PTX(Arm2)(Figure 1)
[10, 13]. Women with estrogen-receptor- (ER) positive or
progesterone-receptor-(PgR)positivetumorsreceived20mg
of tamoxifen per day for ﬁve years. Tamoxifen was originally
initiated on day 1 of the ﬁrst cycle of AC, but this was
amended in response to the ﬁndings of Southwest Oncology
Group trial 8814 to require that hormonal therapy be
started after chemotherapy [39]. A second amendment fol-
lowing the report of the arimidex, tamoxifen alone or in
combination (ATAC) trial permitted treatmentwith anastro-
zole in postmenopausal ER- or PgR-positive patients [40].
The North Central Cancer Treatment Group trial N9831
(NCCTG N9831) compared four cycles of AC followed by
12 weeks of weekly paclitaxel (wkly-PTX) (Arm A, reference
arm) with the same regimen plus 52 weeks of wkly-HER
either following wkly-PTX (Arm B) or beginning on day
1o fw k l y - P T X( A r mC )( Figure 1)[ 10, 41]. Women with
ER- or PgR-positive tumors were originally scheduled to
receive 20mg of tamoxifen per day for ﬁve years, initiated
after chemotherapy. Following the ATAC trial, however, the
protocol was amended to permit postmenopausal ER- orChemotherapy Research and Practice 3
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0.4%
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Severe
CHF
0.9%
3.8%
0.3%
2.8%
3.3%
0%
0.6%
NR
0.7%
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0.4%
1.7%
NSABP B-31
AC → PTX
AC → PTX + HER
NCCTG N9831
AC → PTX
AC → PTX → HER
AC → PTX + HER
BCIRG 06
AC → DTX
AC → DTX + HER
TCH + HER
FinHER
DTX or VNR → FEC
DTX or VNR + HER
→ FEC
HERA
CTx (+/−)R T
CTx (+/−)R T→ HER (1y)
CTx (+/−)R T→ HER (2y)
(1y)
(2y)
PACS 04
FEC or ED
FEC or ED → HER (1y) (1y)
Figure 1: Schema of treatment regimens and associated cardiotoxicity in the large adjuvant trastuzumab trials. AC, doxorubicin 60mg/m2
and cyclophosphamide 600mg/m2, q3w; PTX, paclitaxel 175mg/m2, q3w (NSABP B-31) or 80mg/m2, qw (NCCTG N9831); HER,
trastuzumab loading dose of 4mg/kg followed by 2mg/kg, qw (NSABP B-31, NCCTG N9831, and FinHER and in combination with DTX in
BCIRG 06) or loading dose of 8mg/kg followed by 6mg/kg, q3w (HERA and PACS 04 and at trastuzumab alone phase in BCIRG 006); CTx,
adjuvant and/or neoadjuvant chemotherapy; RT, adjuvant radiation therapy; DTX, docetaxel 100mg/m2,q 3 w ;T C H ,d o c e t a x e l7 5m g / m 2
and carboplatin area under the curve (AUC) 6, q3w and trastuzumab loading dose of 4mg/kg followed by 2mg/kg, qw; VNR, vinorelbine,
25mg/m2, qw; FEC, ﬂuorouracil 600mg/m2, epirubicin 60mg/m2, and cyclophosphamide 600mg/m2, q3w (FinHER) or ﬂuorouracil
500mg/m2, epirubicin 100mg/m2, and cyclophosphamide 500mg/m2, q3w (PACS 04); ED, epirubicin 75mg/m2 and docetaxel 75mg/m2,
q3w; CHF, congestive heart failure; NR, not reported.
PgR-positivepatientstobetreatedwithanyaromataseinhib-
itor. Because of the similarity of Arms 1 and 2 in the NSABP
B-31, and Arms A and C in the NCCTG N9831, combined
analysis was performed and the results were published as a
full paper [10], with subsequent updated data available in a
conferenceabstractform[13].IndividualdataoftheNCCTG
N9831 is only available as a conference abstract at this time
[41, 42].
The Breast Cancer International Research Group 006
(BCIRG 006) compared four cycles of AC followed by four
cycles of triweekly docetaxel (tri-DTX) (reference arm) with
the same regimen plus 52weeks of trastuzumab (weekly at
DTX phase and triweekly thereafter) beginning on day 1 of
tri-DXT(Figure 1).Thistrialisdistinguishedfromtheothers
by the involvement of a nonanthracycline regimen, consist-
ing of docetaxel, carboplatin, and trastuzumab (TCH), with
the aim of reducing cardiotoxicity [11, 12]. The results of
thisstudyarepresentlyavailableonlyasaconferenceabstract
[11, 12].
The Herceptin Adjuvant (HERA) study diﬀered from the
other trials in that patients were randomized at the point
of completion of standard adjuvant chemotherapy with or
without radiotherapy to either observation alone, one year
of triweekly trastuzumab (tri-HER), or two years of tri-HER
(Figure 1)[ 9, 14]. Adjuvant endocrine therapy, primarily
20mg of tamoxifen per day, was given after chemotherapy to
women with ER- or PgR-positive disease. An amendment to
the protocol allowed aromatase inhibitors to be used instead
of or in sequence with tamoxifen [9]. Initial and two follow-
up data from observation and one year of trastuzumab were
published in 2005, 2007, and 2011, respectively [9, 14, 43].
Data from two years of trastuzumab is not available at this
point.
The Finland Herceptin (FinHER) study was designed to
compare three cycles of triweekly vinorelbine with tri-DXT,
both followed by three cycles of ﬂuorouracil, epirubicin, and
cyclophosphamide (FEC) (Figure 1)[ 15, 16]. For HER2-
positive patients, patients were additionally randomized at
the tri-VNR or tri-DXT phase to receive or not receive
tri-HER. Patients with ER- or PgR-positive tumors initially
received 20mg of tamoxifen per day for ﬁve years. The
protocol was amended during the trial to allow the switchingChemotherapy Research and Practice 5
of tamoxifen to an aromatase inhibitor for postmenopausal
women after 2 to 3 years of tamoxifen use to complete the
5-year administration of a hormonal agent and to allow
administration of an aromatase inhibitor for a further 2
to 3 years after the completion of 5-year administration of
tamoxifen [15]. Distinct from the other trials, trastuzumab
wasgivenforonlynineweeksinthisstudy.Initialresultswere
published in 2006 and the ﬁnal results in 2009 [15, 16].
The Programmes d’Actions Concert´ ees Sein (PACS) 04
trial ﬁrst randomly assigned patients to six courses of
ﬂuorouracil, epirubicin 100mg/m2, and cyclophosphamide
(FEC100) or six courses of epirubicin 75mg/m2 and doc-
etaxel (ED75) and then further randomized HER2-positive
p a t i e n t st os e q u e n t i a lt r i - H E Rf o r1y e a ro rt oo b s e r v a t i o n
(Figure 1)[ 44]. Endocrine therapy was mandatory for
patients with ER- or PgR-positive tumors. Premenopausal
patients were given 20mg of tamoxifen per day for 5 years,
while postmenopausal patients received endocrine therapy
with either anastrozole or tamoxifen at the discretion of
investigator [44].
4.2. Eﬃcacy Data. Although the PACS 04 trial enrolled only
node-positive patients, other baseline characteristics of the
disease were quite similar between the six trials (Table 1).
All six trials established recurrence-free survival (RFS)
(FinHER) or disease-free survival (DFS) (the others) as the
primary endpoint with subtle diﬀerence in the deﬁnition
regarding whether to count ductal carcinoma in situ (DCIS)
or second nonbreast malignancy as an event [9, 10, 16].
AlthoughintheﬁnalreportoftheFinHERstudytheprimary
endpoint was amended to be distant disease-free survival
[15], we adopted the eﬃcacy data from the initial report in
Table 1 for better comparison between the trials.
All but the PACS 04 study showed the superiority of
trastuzumab-containing regimens over standard regimens
without trastuzumab, with statistical signiﬁcance, with the
most recent hazard ratios (HRs) ranging from 0.42 to 0.76
(Table 1)[ 12–14, 16, 41, 44]. In PACS 04, trastuzumab did
not signiﬁcantly improve DFS with HR of 0.86 (95%CI
0.61–1.27; P = 0.41) [44]. Overall survival (OS), set as a
secondary endpoint in each trial, tended to be improved
with trastuzumab-containing regimens compared to non-
trastuzumab regimens, again with the exception of the PACS
04 trial (Table 1) .T h em o s tr e c e n tH R sf o rO Si nt r i a l s
other than PACS 04 ranged from 0.41 to 0.86, and P values
were less than 0.05, except for those for Arm B (sequential
trastuzumab) in the NCCTG N9831, and trastuzumab-
containing regimens employed in the HERA and FinHER
studies (Table 1)[ 12–14, 16, 41, 44]. HR for OS in PACS 04
was 1.27 with the wide 95% CI of 0.68–2.38, possibly due to
small sample size (Table 1).
4.3. Target Patients for Treatment with Trastuzumab
4.3.1. HER2 Measurement. With the clinical development of
anti-HER2 agents, including trastuzumab, methods for eval-
uating the expression level of HER2 has also evolved. In the
six trastuzumab adjuvant trials, HER2 positivity was evalu-
ated with immunohistochemistry (IHC), ﬂuorescence in situ
hybridization (FISH), or chromogenic in situ hybridization
(CISH), either alone or on combination. All six trials stip-
ulated that central conﬁrmation of HER2-positivity using
these methods was mandatory either from the beginning or
after protocol amendment [44, 45].
IHC is a semiquantitative method which detects HER2
p r o t e i nl e v e l so nt h ec e l ls u r f a c ei nb r e a s tc a n c e rs p e c i m e n s .
Currently, the US Food and Drug Administration (FDA) has
approved three types of IHC system to determine HER2 sta-
tus: HercepTest (Dako, Glostrup, Denmark), Pathway anti-
HER2/neu (Clone CB11) (Ventana-Roche, Tucson, Ariz,
USA), and InSite HER2/neu CB11 (Biogenex, San Ramon,
Calif, USA). In each system, IHC scoring is performed sub-
jectively as 0, 1+, 2+, or 3+ based on the intensity of mem-
brane staining in >10% of cancer cells [45].
FISH or CISH is a DNA-based assay that directly meas-
ures HER2 gene ampliﬁcation. FISH testing results are sem-
iquantitative, based on the absolute number of HER2 signals
or the average ratio of HER2 signals to CEP17 (a probe
against the chromosome 17 centromeric sequences) signals
in nonoverlapping interphase nuclei of the lesion. The
FDA has approved three types of FISH testing: PathVysion
(Vysis, Downers Grove, Ill, USA), in which a ≥2.0 ratio
HER2/CEP17 is considered ampliﬁed; INFORM (Ventana-
Roche), in which ≥5 . 0g e n ec o p i e so fH E R 2i sc o n s i d e r e d
ampliﬁed; and HER2 FISH pharmDx (Dako), in which a
≥2.0 ratio of HER2/CEN-17 is considered ampliﬁed. In
addition, one CISH test has been approved: SPOT-Light
(Invitrogen, Carlsbad, Calif, USA), in which 10 dots, or large
clusters, or a mixture of multiple dots and large clusters in
50% of tumor cells is considered ampliﬁed.
To improve the accuracy of HER2 testing and its utility
as a predictive marker for anti-HER2 agents, the American
Society of Clinical Oncology/College of American Patholo-
gists (ASCO/CAP) updated their guideline recommendation
for HER2 testing in 2007 [45]. Positivity for HER2 is demon-
strated by either IHC HER2 3+, deﬁned as uniform intense
membrane staining of >30% of invasive tumor cells or FISH
ampliﬁed, deﬁned as a ratio of HER2 to CEP17 >2.2, or
an average HER2 gene copy number >6 signals/nucleus for
those test systems without an internal control probe. They
alsorecommend that if initial results forHER2 are equivocal,
that is, HER2 2+, IHC or FISH ratio 1.8–2.2, or HER2
gene copy 4.0–6.0, validated IHC, FISH, or CISH should be
performed or repeated.
It should be noted that the new ASCO/CAP HER2 pos-
itivity criteria are stricter than those of the manufacturers.
In the ﬁve adjuvant trastuzumab trials with the exception
of PACS 04, positive IHC membrane staining in 10% to
less than 30% of cells and an HER2/CEP17 ratio of 2–2.2,
were eligible based on the manufacturers’ criteria. In the
PACS 04 trial, while the same manufacturers’ criteria were
used for IHC, only IHC 2+ cases were sent to FISH and
HER2/CEP17 ratio ≥2.2 was deﬁned as positive [44].
But, these cases would have been equivocal based on the
ASCO/CAP guideline. To assess the inﬂuence of diﬀerential
criteria on study result, tumor samples in the NCCTG
N9831 were reevaluated using the ASCO/CAP criteria
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(by IHC, 3.7%; FISH, 1.4%; both, 1.7%) of patients did not
meet the ASCO/CAP 2007 HER2 positivity guidelines [42].
Becausethereisnoevidencetosupportthatthepatientswith
equivocal HER2 positivity should be excluded from adjuvant
treatment with trastuzumab, the drug is generally given as a
part of systemic therapy.
4.3.2. Deﬁnition of High Risk no Disease. Among the six
trials, only the PACS 04 trial enrolled only node-positive
patients, whereas the other ﬁve trials enrolled both node-
positive and negative high-risk patients. However, they
varied in their deﬁnition of high-risk. Both the NCCTG
N9831 and NSABP B-31 trials deﬁned tumors of more than
2cm in diameter for hormone receptor- (HR-) positive dis-
ease and more than 1cm in diameter for HR-negative disease
as high risk (Table 1) .T h eH E R As t u d ye n r o l l e dn o d e -
negative patients with primary tumors that were more than
1cm regardless of HR status, while the BCIRG 006 trial
considered high risk as node-negative disease with tumors
that were either more than 2cm in diameter, HR-negative,
or histological grade (HG) 2 or 3, or with a patient age of
younger than 35 years. Finally, the FinHER study enrolled
node-negative patients with tumors that were more than
2cm in diameter and PgR-negative. Of note, no trials in-
volved node-negative disease with a primary tumor size of
1cm or less, and no deﬁnitive threshold for treatment with
orwithouttrastuzumabhasaccordinglyyetbeenestablished.
The often-utilized St Gallen International Expert Con-
sensus, renewed in 2009, included the following statement:
“patients with tumors of <1cm in size without axillary nodal
involvement and without other features indicating increased
metastatic potential (e.g. vascular invasion) might not need
adjuvant systemic therapy” [46]. The National Comprehen-
sive Cancer Network (NCCN) Clinical Practice Guideline,
on the other hand, recently raised its category of evidence
and consensus from Category 3A (reﬂecting the presence
of major disagreement among NCCN panel members) to
Category 2A (based on a lower-evidence but uniform NCCN
consensus) for consideration of adjuvant trastuzumab in
women with node-negative tumors that are 0.6 to 1.0cm
(NCCN, Version 2, 2011). This update was based on several
retrospective studies which suggested that HER2-positivity is
a poor prognostic factor even in patients with node-negative
tumors ≤1.0cm [47–49]. The consideration of trastuzumab
use for node-negative small tumors is also supported by
a recently published article by Banerjee et al. [50]. These
authors reviewed retrospective studies which followed the
outcome of patients with HER2-positive, node-negative, and
1cm or smaller tumors [50]. They found that while relapse
in patients with HER2-positive small tumors was less than
10% at 10 years after diagnosis, it rose to 16% to 17% and
21%to29%at15and20yearsafterdiagnosis,respectively,in
those studies with long-term followup [50]. They also noted
that patients with relatively small tumors (1.1–2.2cm) in the
HERA study had the same magnitude of risk reduction with
trastuzumab[50].Therefore,althoughaﬁnaldecisiononthe
usedoftrastuzumabinthesepatientsshouldbelefttoclinical
judgment, physicians should at least discuss this issue with
patients.
4.4. Treatment Duration. In addition to one-year trastuzum-
ab and reference arms, the HERA study also established a
2-year trastuzumab arm [9]. No eﬃcacy or safety data for
this longer arm is yet available, so the value of adminis-
tration beyond one year is unclear. The FinHER study was
distinguished from the other large trials by its administra-
tion of trastuzumab for only 9 weeks, concurrently with
vinorelbineordocetaxel[15,16].Despitethisshortduration,
trastuzumab provided a dramatic improvement in eﬃcacy
overthenontrastuzumabcontrol,withanHRof0.42forRFS
[16]. Multiple randomized trials comparing the standard 1
year of trastuzumab therapy with a shorter duration are
ongoing. In one, the synergism or long duration (SOLD)
Study conducted by the Finnish group following the FinHER
trial, three cycles of tri-DXT in combination with wkly- or
tri-HER followed by three cycles of FEC was compared with
the same regimen followed by 14 doses of additional tri-HER
to give a total duration of trastuzumab therapy of one year.
Results of these trials will provide an insight into the optimal
duration of adjuvant trastuzumab (NCT00593697). Until
then, however, one-year trastuzumab should be considered
the current standard, because this was the duration used by
the majority of the randomized trials.
4.5. Concurrent or Sequential. Joint analysis of the NCCTG
N9831 and NSABP B31 trials, which compared a non-
trastuzumab control and trastuzumab given concurrently
with paclitaxel, produced the impressive HR for DFS of 0.49
[13]. The NCCTG N9831 involved another arm in which
trastuzumab was given sequentially after the completion
of wkly-PTX (Arm B, Figure 1). Individual data for this
trial comparing reference Arm A (nontrastuzumab) with
sequential arm (Arm B) is available in conference abstract
form, and show an HR for Arm B of 0.67, which is
somewhat less robust than that in the joint analysis of
NCCTG N9831 and NSABP B31 trials [41]. Further, the
concurrent arm was superior to the sequential arm, with an
HR for DFS of 0.75 (95% CI 0.60–0.94; P = 0.0190) [41]
even though this comparison was not the primary analysis
of the NCCTG N9831. In addition, the HERA study, in
which trastuzumab was given sequentially after completion
of standard chemotherapy, again produced the less robust
HR for DFS of 0.76, which is less than the joint analysis of
the NCCTG N9831 and NSABP B31 trials. Further, in PACS
04 trial, trastuzumab given after completion of six courses
of FEC100 or ED did not provide any signiﬁcant impact on
DFS compared to observation. Therefore, it is very likely that
trastuzumab is more active when given concurrently with
than sequentially after chemotherapy as long as the same
chemotherapy regimen is employed.
4.6. Cardiotoxicity. Although trastuzumab is generally very
well tolerated, it occasionally impairs cardiac function
due to myocardium damage. While anthracycline-induced
cardiotoxicity is dose-dependent and results mainly from
oxidative mechanisms that lead to the apoptosis and necro-
sis of cardiomyocytes, trastuzumab-induced cardiotoxicity
is generally not dose-dependent and does not show the
ultrastructural changes typical of anthracycline [51, 52].Chemotherapy Research and Practice 7
Although the mechanism of trastuzumab-associated cardiac
dysfunction is not precisely known, it has been suggested
that HER2 may have a protective role for cardiomyocytes
[53]. No consistent risk factors for trastuzumab-associated
cardiotoxicity have been identiﬁed, out older age and need
for antihypertensive agents baseline left ventricular ejection
fraction (LVEF) <55% were found to be associated with
incidence of cardiac events in the NCCTG N9831 and
NSABP B31 trials [54, 55].
As summarized in Figure 1, the incidence of cardiac dys-
function and severe chronic heart failure (CHF) in trastuz-
umab-containing treatment in the phase III trials ranged
from 3.0% to 14.2% and from 0.4% to 3.8%, respectively.
Given their diﬀering deﬁnitions of cardiac dysfunction and
severe CHF, direct comparison between regimens requires
prudence. Nevertheless, when we see much lower incidence
of cardiotoxicity in the HERA study than that in the
NSABP B-31 study, it appears that a high incidence of car-
diotoxicity should be expected when trastuzumab is given
concurrently with chemotherapy (Figure 1). On the other
hand, the direct comparison of concurrent versus sequen-
tial administration of trastuzumab in the NCCTG N9831
showed only minimally reduced cardiotoxicity in the latter
[55]. The PACS 04 trial also had high incidence of systolic
dysfunction despite sequential administration of trastuz-
umab after completion of six cycles of FEC100 or ED75
[44]. Considering the fact that in the HERA study only
one-fourth of patients took taxanes before trastuzumab and
median cumulative dose of anthracyclines were relatively low
(238 and 405mg/m2 for doxorubicin and epirubicin, respec-
tively), high dose of anthracycline and a taxane before
initiating sequential trastuzumab may be associated with
highercardiotoxicity.Relevanttothis,trastuzumabwasgiven
before anthracycline-based chemotherapy in the FinHER
study only, which had a very low incidence of severe CHF
(one patient) [15]. Although this may have been caused by
the shorter duration of trastuzumab therapy than in the
other trials, as discussed below, this, nevertheless, supports
the possibility that trastuzumab after anthracycline therapy
hampers the heart’s repair mechanisms.
In the BCIRG 006 trial, a nonanthracycline regimen
(TCH) was included owing to concerns of cardiotoxicity
caused by trastuzumab use following anthracycline. This
regimen was indeed associated with lower cardiotoxicity
than those containing anthracycline [11, 12]. It should be
noted, however, that decrease in risk with TCH appears
somewhat smaller than that with AC followed by doc-
etaxel/trastuzumab (HR for DFS, AC followed by doc-
etaxel/trastuzumab versus TCH, 0.64 versus 0.75), notwith-
standingthatthetrialwasnotdesignedtocomparethesetwo
regimens [12].
Another potential approach to avoiding trastuzumab-
associated cardiotoxicity is to shorten the duration of ther-
apy, as attempted in the FinHER study. These investigators
appear to have achieved this particular goal, with even a
lower incidence of systolic dysfunction and symptomatic
CHFintheHER2-containingarmthaninthenontrastuzum-
ab control arm [16]. As discussed above, however, the degree
to which duration can be shortened without decrementing
eﬃcacy remains unknown.
Radiation after breast surgery has been considered a
cardiac risk. While in the HERA and PACS 04 studies and
the FinHER study postsurgical radiotherapy was given se-
quentially before and after trastuzumab, respectively, it was
done concurrently with trastuzumab in the other four trials.
As the HERA and FinHER studies had a lower incidence of
cardiotoxicity, it remains possible that the concurrent use
ofradiotherapyandtrastuzumabiscardiotoxic.Ontheother
hand, however, an unplanned analysis of patients treated
in the N9831 trial revealed no diﬀerence in the frequency
of cardiac events between patients treated with or with-
out radiotherapy even in the trastuzumab-containing arm
[56]. The delivery of radiation therapy concomitantly with
trastuzumab is therefore generally considered safe.
4.7. Adjuvant Trastuzumab without Chemotherapy. Consid-
eration has been given to the possibility of adjuvant
trastuzumab therapy without chemotherapy, particularly
when the patient is old or has a comorbidity, or the tumors
are node-negative, ER- or PgR-positive, and small. In the
metastatic setting, a phase III trial comparing anastrozole
plus trastuzumab with anastrozole alone as ﬁrst-line therapy
for postmenopausal HER2- and hormone receptor-positive
breast cancer showed combination therapy was superior in
terms of progression-free survival (PFS) and response rate
[57]. However, the combination of endocrine therapy and
trastuzumab without chemotherapy remains unproven in
the adjuvant setting, and further data is accordingly needed
before the elimination of chemotherapy can be justiﬁed. In
this regard, a phase III trial comparing trastuzumab mon-
otherapy with trastuzumab plus chemotherapy in HER2-
positive elderly breast cancer patients is currently underway
(NCT01104935).
5. Role of LapatinibinAdjuvantSettings
5.1.RationaleofLapatinibUseinAdjuvantTherapyforHER2-
Positive Breast Cancer. Lapatinib is a dual EGFR/HER2 tyro-
sine kinase inhibitor [58]. In preclinical models, lapatinib
has been shown to overcome resistance to trastuzumab, in-
hibiting phosphorylation of HER2 and overall growth in
HER2-overexpressing breast cancer cell lines speciﬁcally
selected for their in vitro resistance to trastuzumab [59].
Additionally, lapatinib inhibited growth of cells that express
p95 HER2, which is truncated and lacks an extracellular
domainand,therefore,hasthepotentialtodevelopresistance
to trastuzumab [60, 61]. Supporting the role of lapatinib
as a backup drug for trastuzumab, a randomized phase III
trial comparing capecitabine in combination with lapatinib
to capecitabine alone in 399patients with HER2-positive
recurrent/metastatic breast cancer who had progressed with
the anthracycline, taxane, and trastuzumab, reported that
overall response was superior in the lapatinib-receiving arm
(23.7% versus 13.9%; P = 0.017), as was median time to
progression(27.1versus18.6weeks,P<0.001),whileoverall
survival tended to be longer [62].8 Chemotherapy Research and Practice
Unlike trastuzumab, lapatinib has been suggested to
cross the blood-brain barrier, which rationalizes its use in
patients with central nervous system (CNS) metastases. In
a phase II trial of lapatinib in 39patients with HER2-positive
breastcancerwithbrainmetastases,twopatientsexperienced
partial response based on the response evaluation criteria in
solid tumors (RECISTs) criteria, and ﬁve additional patients
experienced at least a 30% shrinkage of CNS lesions [63].
With regard to cardiac safety, prospective data collected
in 44 clinical studies of lapatinib (N = 3,689) revealed a low
incidence of cardiac events potentially caused by lapatinib
(1.6%) [64].
5.2.RationaleofLapatinibinCombinationwithTrastuzumab.
A preclinical study of lapatinib in combination with tra-
stuzumab reported that survivin was more strongly down-
regulated and apoptosis was more strongly induced with
this combination than with either agent alone [65]. Another
preclinical study showed that lapatinib alone or in combi-
nation with trastuzumab trastuzumab inhibited HER2 phos-
phorylation, prevented receptor ubiquitination, and resulted
in the accumulation of inactive HER2 at the cell surface
of HER2-overexpressing breast cancer cell lines, which led
to the subsequent enhancement of ADCC by trastuzumab
[66]. Consistent with the preclinical data, a recent phase
III clinical trial comparing lapatinib and trastuzumab in
combination to lapatinib alone in HER2-positive metastatic
breast cancer patients who had progressed on trastuzumab-
based regimens reported that progression-free survival as the
primary endpoint was better in the combination arm than
in that with lapatinib alone (hazard ratio [HR] = 0.73; 95%
CI, 0.57 to 0.93; P = .008) [67]. Furthermore, in the neoad-
juvant lapatinib and/or trastuzumab treatment optimisation
(Neo-ALTTO trial), 455 preoperative breast cancer patients
with HER2-positive tumors received an initial 6 weeks of
lapatinib, trastuzumab, or their combination, followed by
another 12 weeks of the same anti-HER2 therapy plus wkly-
PTX prior to deﬁnitive surgery. The ﬁrst results, presented at
the San Antonio Breast Cancer Symposium (SABCS) 2010,
showed the highest pathological complete response (pCR)
rate, the primary endpoint of the trial, in the combination
arm (pCR rate [%]; lapatinib versus trastuzumab versus
combination; 24.7 versus 29.5 versus 51.3; P = .34 for
lapatinib versus trastuzumab and P = .001 for trastuzumab
versus combination).
While this accumulating evidence supports the superi-
ority of lapatinib and trastuzumab combination to either
therapy alone, its role in adjuvant therapy remains to be
revealed in the ALTTO study, as discussed below.
5.3. ALTTO Trial. The ALTTO trial is a large, randomized
phase III trial designed to evaluate the role of lapatinib in
adjuvant treatment for HER2-positive breast cancer patients
(Figure 2)[ 68]. Node-positive and node-negative patients
with tumors ≥1.0cm in greatest diameter were eligible,
similar to the trials of adjuvant trastuzumab. Unlike these
trials; however, HER2-positivity was evaluated following the
ASCO/CAP guideline, so that patients with equivocal HER2-
positivity were excluded. The ALTTO trial is comparing
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Figure 2: Schema of the ALTTO trial; DC, docetaxel and carbo-
platin.
trastuzumab for 1 year as the reference arm with either
lapatinib for 1 year, trastuzumab for 6 months followed
by lapatinib for 6 months, and lapatinib in combination
with trastuzumab for 1 year. This trial has two pragmatic
designs; lapatinib and/or trastuzumab are given after the
completion of anthracycline-based chemotherapy (Design 1,
Figure 2), concomitantly with taxanes (Design 2, Figure 2),
or with a nonanthracycline regimen (docetaxel plus carbo-
platin) (Design 2B, Figure 2). Designs 1, 2, and 2B were set
referring to the HERA, NSABP B21 and NCCTG N9831, and
BCIRG 006 trials, respectively. Designs 1 and 2 have already
completed accrual, and Design 2B will complete accrual by
early 2011. The results will provide answers about the role
of lapatinib in adjuvant treatment for HER2-positive breast
cancer.Chemotherapy Research and Practice 9
6. FutureDirections
6.1. Anti-HER2 Agents in HER2-Negative Population. In
early clinical trials of trastuzumab for metastatic breast
cancer,patientswithHER22+byIHCwereenrolledtogether
with HER2 3+ patients. Because subset analysis showed that
the beneﬁt of trastuzumab was none or smaller in HER2
2+ patients [5, 69], virtually all subsequent clinical trials of
trastuzumabwerelimitedtopatientswithHER23+orFISH-
positive disease.
In the NSABP B-31 trial, HER2 positivity was initially
evaluated based on institutional testing, but excessive false
positive HER2 results led to a change to mandatory conﬁr-
mation by the central oﬃce [70]. Among the 1787patients
with follow-up data in the trial, 174patients had breast can-
cers that turned out to be HER2-negative (9.7%) on central
review [71]. Interestingly, these patients also appeared to
beneﬁt from trastuzumab (HR for disease-free survival, 0.34;
95%CI, 0.14 to 0.80; P = .014) [71]. Although this analysis
was exploratory in a small subset, it at least raised a question
of whether the beneﬁt of adjuvant trastuzumab is really
limited to patients with HER2-positivity based on today’s
criteria.
Answering this question will require a phase III trial of
adjuvant trastuzumab in women with breast cancers that
do not meet established criteria. Additionally, reﬁnement
of HER2 testing methodology may be required. In their
comparative analysis of 568 breast cancer tumor samples for
HER2 with FISH according to the ASCO/CAP guideline and
quantitative reverse transcriptase PCR (qRT-PCR) in central
laboratories [72], Baehner et al found a high concordance
rate of 97% (95%CI, 96%–99%) between the two method-
ologies [72]. Given that qRT-PCR is faster than FISH and
generally more quantitative than FISH or IHC, it might be
a candidate for next-generation HER2 testing.
6.2. Newer Anti-HER2 Agents
6.2.1. Pertuzumab. Pertuzumab is another monoclonal anti-
body against the extracellular domain of HER2 protein, but
it attaches to a diﬀerent epitope of HER2 from trastuz-
umab. Pertuzumab is believed to inhibit heterodimer for-
mation between HER2 and EGFR or HER3 [73]. While
the HER2/HER3 heterodimer is considered important in
HER2-driven cell signaling, a preclinical study showed that
the heregulin-dependent HER2/HER3 heterodimer is not
disrupted by trastuzumab, but it is disrupted by pertuzumab
[32]. In a phase II clinical trial involving combination treat-
ment with pertuzumab and trastuzumab in HER2-positive
metastatic breast cancer patients, treatment produced a
response rate and disease control rate of 24.2% and 50%,
respectively[74].Intheneoadjuvantsetting,theneoadjuvant
study of pertuzumab and herceptin in an early regimen
evaluation (NeoSphere) trial randomized 417patients with
centrally conﬁrmed HER2-positive breast cancer to either
docetaxel plus trastuzumab (HD, reference arm, n = 107),
docetaxel, trastuzumab, and pertuzumab (HDP, n = 107),
pertuzumab plus trastuzumab (HP, n = 107), or docetaxel
plus pertuzumab (DP, n = 96). Patients received four cycles
of therapy prior to surgery. The results presented at SABCS
2010 showed that the pCR rate, the primary endpoint, was
signiﬁcantlyhigherintheHDParmandlowerintheHParm
comparedtothereferenceHDarm(pCRrate[%];HDversus
HDPversusHPversusDP;29.0versus45.8versus16.8versus
24.0; P = .0141 for HD versus HDP). These studies suggest
that the addition of pertuzumab to standard trastuzumab-
based treatment might enhance eﬃcacy in both metastatic
and operable HER2-positive breast cancer.
6.2.2. Trastuzumab-DM1. Trastuzumab-DM1 is comprised
oftrastuzumab,DM1,aninhibitoroftubulinpolymerization
derived from maytansine, and the stable [N-maleimido-
methyl]cyclohexane-1-carboxylate (MCC) linker that conju-
gates DM1 and trastuzumab. The compound is designed to
eﬃciently deliver DM1 to HER2-overexpressing cancer cells.
Preclinical studies have demonstrated the growth-inhibitory
eﬀect of trastuzumab-DM1 in HER2-overexpressing and
trastuzumab-resistant cells [75]. In a phase II trial involving
HER2-positive metastatic breast cancer patients who had
experienced disease progression despite trastuzumab-based
therapy (n = 112), trastuzumab-DM1 yielded a response
rate and progression-free survival of 26.9% and 4.6 months,
respectively [76]. Importantly, trastuzumab-DM1 demon-
strated similar antitumor activity and a response rate of
24.2% even in patients previously treated with lapatinib
and trastuzumab (n = 66) [76]. Feasibility and eﬃcacy
of trastuzumab-DM1 in adjuvant or neoadjuvant treatment
for HER2-positive early breast cancer are currently under
evaluation in a phase II study (NCT01196052).
6.2.3. HER2 Vaccines. Vaccines and adoptive immunother-
apy targeting the HER2 extracellular domain have been
tested in clinical trials, with results showing that signiﬁcant
levels of durable T-cell HER2 immunity can be generated
with active immunization without signiﬁcant autoimmunity
consequences against normal tissues [77]. Preliminary data
from clinical trials testing the potential use of HER2 vaccines
in adjuvant therapy for high-risk breast cancer patients have
shown promising results [78].
7. Conclusions
The integration of trastuzumab into conventional adjuvant
chemotherapy has signiﬁcantly improved treatment out-
comes in patients with HER2-positive early breast cancer.
Although it is impossible to specify one particular regimen
as superior, these trials suggest that anthracyclines followed
bytrastuzumabgivenconcurrentlywithtaxanesappearmost
promising albeit at the price of a relatively high incidence
of cardiotoxicity. With the evidence available today, it is
left to clinical judgment to determine whether patients with
equivocal HER2-positivity based on ASCO/CAP or with a
tumor size of 0.6 to 1.0cm should be given trastuzumab,
and what level of cardiac risk warrants less cardiotoxic
trastuzumabregimens,namely,thosewithashorterduration
of trastuzumab, sequential use, and the avoidance of anthra-
cyclines. The ALTTO trial will clarify the role of lapatinib in10 Chemotherapy Research and Practice
adjuvant treatment for HER2-positive breast cancer, as it is
or in combination with trastuzumab. Role of newer class of
anti-HER2 agent in adjuvant treatment for breast cancer will
also be evaluated in clinic in the near future.
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